OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Genetics and Genomics of Acute Promyelocytic Leukemia
Submission Deadline: June 15, 2020 (Open) Submit Now
Racha El-Hajj Ghaoui, Ph.D
Senior Scientist, Department of Cytogenetics, Sydney Genome Diagnostics, Sydney, Australia
Research Interests: Fluorescence In Situ Hybridisation; human cytogenetics; oncology and blood cytogenetics
About This Topic
Acute promyelocytic leukaemia (APL) is an aggressive and rare sub-type of acute myeloid leukaemia (AML) and accounts for only 10% of all AML diagnoses. PML-RARA gene fusion most often arises via the classic t(15;17)(q24.1;q21.2) translocation. This special issue will cover the unique cases of paediatric and adult APL and highlights the unusual findings in this type of leukaemia and its variants including therapy related APL..
In this issue, you are invited to present all the clinical aspects of APL from diagnosis to treatment. Also, discuss the genetics and genomics (genome sequencing) background of this leukaemia subtype, including gene mutation (i.e. FLT3) status which can predict an early death in APL. It would also be important highlighting the Cytogenetics [karyotype and fluorescence in situ hybridisation] and molecular testing [RT-PCR] for a rapid diagnosis of APL which is important due to the high risk of disseminated intravascular coagulation leading to internal bleeding and death. Immediate treatment with both all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has improved the prognosis for APL patients, especially if consolidated with anthracycline, leading to a disease-free survival..
All new studies and technologies which have been applied to improve disease classification, clinical care, and novel therapeutic approaches in AML/APL would make a significant contribution to this special issue.